BioCentury
ARTICLE | Company News

NanoBio deal

August 8, 2011 7:00 AM UTC

NanoBio received exclusive, worldwide rights from NIH to an antigen against respiratory syncytial virus (RSV). NanoBio said it will combine its NanoStat adjuvant technology with the antigen for use in...